Aim Immunotech Inc. · AMEX:AIM
Aim Immunotech — Investor Presentation (September 2019)
16 slides from Aim Immunotech's investor presentation, Sep 9, 2019
Slide 1: Revolution _
Revolution _
Slide 2: Forward-Looking Statements
Forward-Looking Statements Some of the statements included in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, we claim the protection of safe harbor for forward-looking statements contained in the Private
Slide 3: AIM ImmunoTech Inc. Overview
AIM ImmunotTech Inc. Overview AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, as well as immune- deficiency disorders. AIM ImmunoTech has seen success in the field of immuno- oncology, which has guided the co
Slide 4: Ampligen (rintatolimod) Development Pipeline
Ampligen (rintatolimod) Development Pipeline Disease / Indication Pre-clinical Ls ng | mma Approved | ee | Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome* e e e e U.S.*** — Argentina e Ovarian, Colorectal, Renal Cell Carcinoma*, Breast and e e e Melanoma* Cancers xe Pancreatic Cancer e e e Blad
Slide 5: Animal Experiments: Ampligen + Checkpoint Blockade
Animal Experiments: Ampligen + Checkpoint Blockade Synergistically Increased Survival/Anti-tumor Response e At the University of Nebraska, in a pancreatic cancer transgenic mouse model, combining Ampligen with an anti-PD-L1 drug shows a significant synergistic increase in median survival over contro
Slide 6: Ongoing Clinical Trial Objective: Prove Ampligen Reprograms the Tumor Microenvironment
Ongoing Clinical Trial Objective: Prove Ampligen Reprograms the Tumor Microenvironment to Convert ‘Cold’ Tumors Into ‘Hot’ Tumors that will be Responsive to Checkpoint Inhibitors e Increase Intratumoral Effector T (Teff) cells e Decrease Intratumoral Regulatory T (Treg) cells e Goal is to unleash th
Slide 7: Five Ampligen Immuno-oncology Clinical Trials Initiated / Ongoing in the U.S.
Five Ampligen Immuno-oncology Clinical Trials Initiated / Ongoing in the U.S. e Advanced Recurrent Ovarian Cancer - Phase 1 / 2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian cancer at University of Pittsburgh Medical Center. Phase 1 portion establishes intraperitoneal sa
Slide 8: Five Ampligen Immuno-oncology Clinical Trials Initiated / Ongoing in the U.S. - Continued
Five Ampligen Immuno-oncology Clinical Trials Initiated / Ongoing in the U.S. - Continued e Stage 4 Colorectal Cancer Metastatic to the Liver - Phase 2a study of Ampligen as component of chemokine modulatory regimen on colorectal cancer metastatic to liver at Roswell Park Comprehensive Cancer Center
Slide 9: Additional Ampligen Clinical Trials Planned to Be Initiated in 2019-2020, Subject to Funding
Additional Ampligen Clinical Trials Planned to Be Initiated in 2019-2020, Subject to Funding e Early-Stage Triple Negative Breast Cancer - Phase 1 study of chemokine modulation plus neoadjuvant chemotherapy in patients with early-stage triple negative breast cancer is awaiting FDA authorization. The
Slide 10: Expanded Access Program (EAP) with Ampligen as Standalone Treatment in Pancreatic Cancer
Expanded Access Program (EAP) with Ampligen as Standalone Treatment in Pancreatic Cancer e Location: Erasmus University, The Netherlands conducted by Professor Casper van Eijck e — Eligibility: Adults with metastatic or locally advanced pancreatic carcinoma following FOLFIRINOX and adults post-Whipp
Slide 11: Ampligen in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
Ampligen in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) e Just 10 short years ago, the medical consensus was that ME/CFS was a psychological disorder, but today there are a plethora of peer-reviewed medical journal articles that support the proposition that ME/CFS is in fact a medica
Slide 12: Clinical Safety Record of Ampligen (dsRNA)
Clinical Safety Record of Ampligen (dsRNA) e Ampligen has been generally well-tolerated, with almost 100,000 IV doses administered in humans, as well as an intra-nasal and intra- peritoneal safety profile e Approved as safe for commercial use in Argentina e Numerous orphan drug designations have bee
Slide 13: Supplemental Data: Publications Demonstrating the Immunological Activity of Ampligen in Oncology
Supplemental Data: Publications Demonstrating the Immunological Activity of Ampligen in Oncology Only TLR3 agonist to promote selective attraction of CTLs (Teff) with concomitant increase in Teff/Treg ratio in the TME Reference(s)* Theodorika, et al. (2018) Ampligen induces desirable chemokines in t
Slide 14: Supplemental Data: Publications Demonstrating the Immunological Activity of Ampligen - cont'd
Supplemental Data: Publications Demonstrating the Immunological Activity of Ampligen — cont’d Induces dendritic cell maturation: Enhances bioactivity of cancer immunotherapy Reference(s)* Nicodemus, et al. (2010) Promotes optimal dendritic cell maturation and Th1-type responses of healthy donors and
Slide 15: Supplemental Data: Publications Demonstrating Activity of Ampligen in ME/CFS and Antiviral Indications
Supplemental Data: Publications Demonstrating Activity of Ampligen in ME/CFS and Antiviral Indications, and ME/CFS Research A ity Ampligen increases exercise performance in ME/CFS in Phase Ill, placebo-controlled trial References Strayer, et al. (2012) Review of Ampligen clinical activity in ME/CFS
Slide 16: Corporate Headquarters
SalM Corporate Headquarters 2117 SW Highway 484 Ocala, FL 34473 Phone: 352-448-7797 Fax: 352-480-4620 Email: info@aimimmuno.com NYSE American: AIM www.aimimmuno.com ee 16
AIM ImmunoTech — Investor Presentation (September 2019) on 6ix